Evidence and Innovations Targeting Inflammation Post-AMI

In this week’s View, Dr. Eagle looks at the potential value of sodium-glucose cotransporter 2 (SGLT2) agents after transcatheter aortic valve implantation (TAVI). He then explores a new randomized trial, HYPERION, focusing on the addition of sotatercept to lower the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses a state-of-the-art review centered around the use of an anti-inflammatory to lessen cardiovascular events and worse outcomes following acute myocardial infarction (AMI).  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD). He then explores left atrial appendage occlusion (LAAO) in patients with prior intracranial hemorrhage or ischemic stroke. Finally, Dr. Eagle discusses the recently released NEWTON-CABG CardioLink-5 trial on the use of evolocumab in the reduction of saphenous vein graft (SVG) disease rates.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the value of oral semaglutide for weight loss. He then explores whether anticoagulants improve survival in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses the recent release of the ACC Expert Consensus Decision Pathway (ECDP) on tricuspid regurgitation (TR) evaluation and management.     Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the net benefit of intensive blood pressure control between fewer cardiovascular and more adverse events. He then explores non-atherothrombotic myocardial infarction events and spontaneous coronary artery dissection (SCAD) in younger patients – something more commonly found among young women than young men. Finally, Dr. Eagle discusses whether clopidogrel is superior to aspirin for the prevention of major adverse cardiovascular or cerebrovascular events in patients with coronary artery disease (CAD).  Subscribe to Eagle’s Eye View  

Dr. Eagle continues in this week’s View to analyze some of the key clinical content presented at the ESC Congress recently held in Spain. Dr. Eagle examines the TARGET-FIRST trial in which P2Y12-inhibitor monotherapy was compared to dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI).  He then analyzes the results of the ODYSSEY-HCM trial which explored mavacamten versus placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses the ESSENCE-TIMI 73b study that looked at olezarsen and its potential for lowering triglycerides in moderate hypertriglyceridemia with elevated cardiovascular risk.    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at major trials presented at the recent ESC Congress in Spain. First, he discusses the MAPLE-HCM trial that investigates aficamten versus metoprolol monotherapy in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).  He then explores a set of important presentations on beta blocker therapy following myocardial infarction. Finally, Dr. Eagle talks about new research on the use of reconditioned pacemakers that shows promise for strengthening global cardiovascular health.   Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle evaluates the potential value of self-service blood pressure (BP) kiosks and their potential to improve hypertensive health nationwide. He then discusses the FLAVOUR trial and its comparable outcomes with fractional flow reserve (FFR) and intravascular ultrasound (IVUS)-guided treatment for intermediate coronary stenosis. Finally, Dr. Eagle explores how continuous positive airway pressure {CPAP} may improve cardiovascular outcomes in patients with high-risk obstructive sleep apnea (OSA).  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the new ACC/AHA guideline for prevention, detection, evaluation and management of high blood pressure (BP). He then discusses new-onset right bundle branch block (RBBB) post-transcatheter aortic valve replacement (TAVR) and its association with a high risk of permanent pacemaker implantation (PPI). Finally, Dr. Eagle explores gender-affirming hormone therapies and their effect on cardiac repolarization.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at whether compression stockings reduce vasovagal syncope recurrence. He then discusses new concise clinical guidance that addresses the evaluation and management of pericarditis. Finally, Dr. Eagle explores early, safe cardiac rehabilitation for critically ill patients hospitalized with acute decompensated heart failure (ADHF).   Subscribe to Eagle’s Eye View    

In this week’s View, Dr. Eagle looks at the SUMMIT trial and considers how body mass index (BMI) and central adiposity affect tirzepatide outcomes for heart failure with preserved ejection fraction (HFpEF). He then discusses bicuspid aortic valves type 0 (BAV-0) and its association with better long-term prognosis in patients with severe aortic stenosis (AS) undergoing tricuspid aortic valve replacement (TAVR). Finally, Dr. Eagle examines long-term risk of infective endocarditis and why it is significantly higher for mitral valve (MV) replacement versus repair.    Subscribe to Eagle’s Eye View